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In recent years, patient- reported outcome meas-
ures (PROMs) have become increasingly popular 
in clinical practice and clinical trials. In this paper, 
we highlight the need for introducing measures to 
control for the bias associated with these inher-
ently subjective measures and combining PROMs 
with objective outcomes, which do not depend on 
judgement, experience or performance.
PROMs measure the subjective elements of 
patients’ conditions, including health- related 
quality of life, pain intensity, activity limitations, 
participation restrictions, satisfaction or adherence 
to treatment and help to evaluate the burden of 
disease and treatment from patients’ perspectives.1
Originally, PROMs were used in pharmacolog-
ical research to assess treatment effects in condi-
tions such as cancer, in cases where the cure was 
not possible, and quality of life became the primary 
concern.2 In the last 20 years, the use of PROMs 
has increased considerably,1 3 and, currently, those 
outcomes are used to assess the effects of treat-
ment and quality of care2 and to evaluate poli-
cies3 and to inform health economics.4 One of 
the factors that contributed to the popularity of 
PROMs was their recognition by the Food and 
Drug Administration (FDA) and the European 
Medicines Agency (EMA) as a measure of treat-
ment efficacy.1 5 6 The FDA and the EMA define 
PROMs as any outcomes related to the patient’s 
health or treatment that is evaluated directly by 
the patient, without any interpretation by a doctor 
or anyone else.1 6 According to this definition, and 
in contrast to common perception, these outcomes 
do not necessarily measure what is the most 
important to patients or health itself.7 8
The role of PROMs
The main role of PROMs is that they provide 
important indicators of treatment efficacy not 
captured by objective markers or clinical assess-
ments.1 6 They may be used as ‘red flags’ during 
the assessment of acute symptoms and help to 
monitor response to treatment, for example, 
the efficacy of analgesia, especially if they are 
collected in real time.2
Moreover, well- developed PROMs for a specific 
condition may measure treatment effects on 
many domains, which is useful because treatment 
may have a different effect on disease- specific 
outcomes, health status and quality of life.9 
Finally, reporting PROMs improves communica-
tion between the patient and the care provider 
and, in turn, increases patient’s satisfaction with 
treatment2 and, subsequently, helps with adher-
ence to the treatment itself and with patient 
retention.10
Considerations for the use of PROMs
Potential limitations and biases associated with 
PROMs are rarely acknowledged,2 3 5 11 although 
both EMA and FDA recognise that PROMs may 
not be suitable as primary outcomes in open- 
label settings and that they should be supported 
by objective or functional outcomes.1 6 By 
the nature of being subjective, PROMs may 
be affected by internal factors, such as mood, 
expectations, time and sentiments, and external 
factors such as treatment context, interactions 
with the healthcare providers and patients’ soci-
oeconomic situation, which leads to fluctua-
tions in the outcomes. In trials, in which only 
patients with particularly severe symptoms and 
disability are recruited, this variability is higher, 
and PROMs’ fluctuations associated with natural 
regression to the mean might be interpreted 
as a treatment effect.12 Regression towards the 
mean after a different period of time from the 
end of each intervention might inflate type 1 
error. However, some interventions take longer 
to work, and their effects may become apparent 
only after some time causing type 2 error.
Apart from being subjective, some PROMs 
also require patients to make a judgement 
regarding the treatment effects. Patients often 
overestimate benefits and underestimate the 
risks of treatments.13 Under prospect theory, 
the value is assigned to gains and losses rather 
than to final assets, and those values depend 
on experience. This has profound implications 
for comparison of the efficacy, especially if one 
treatment arm is associated with an initial dete-
rioration in function, for example, an operation 
or chemotherapy, followed by a fairly steady 
recovery, and can provide an overall perception 
of significant gain, known as the ‘rebound’ effect 
(figure 1). Moreover, patients are not necessarily 
able to identify an improvement in their own 
health. For example, the improvement measured 
using the maximum forced expiratory volume 
in 1 s in patients with asthma may not trans-
late into a positive change in terms of patient- 
reported improvements when compared with 
placebo.14 Therefore, it is important to combine 
PROMs with functional outcomes in order to 
gain insight into both physiological effect and 
patients’ well- being. Similarly, what patients 
report as important may not be what they 
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actually choose. For example, patients often say that pain relief 
is the most important for them, but many do not take some of 
their pain killers and are willing to accept some level of pain in 
order to be able to function and they do not actually expect to 
be pain free.15 These examples demonstrate that the assessment 
of treatment efficacy requires careful and multidimensional 
approach based on PROMs and functional outcome measures.
PROMs may be able to capture multiple domains, but the 
drawback of using PROMs with a broad outcome set is the 
tendency for patients to report only some of them. Selective 
reporting is a common problem despite reporting guidelines and 
clinical trial registries.16 However, a narrow set of outcomes 
increases the risk of missing clinically meaningful changes. 
Finally, due to variability, PROMs measurements are often cate-
gorised, which reduces reliability and decreases power.17
Strategies to improve the use of PROMs
In open- label settings, patients are likely to exaggerate the 
treatment effect, especially if the treatment is invasive.18 18 19 
Blinding of patients reduces reporting bias as well as a risk 
of unbalanced attrition or cointerventions,18 and blinding of 
doctors or researches reduces observer’s and detection bias; 
however, biases related to unblinded patients tend to be larger 
than those caused by unblinded assessors.19 20 When blinding is 
not possible, PROMs collection should be combined with func-
tional, imaging and biochemical biomarkers adding an element 
of objectivity.1 6
The treatment effect should improve patients’ satisfaction 
and surpass the placebo effect; therefore, when it is important 
to assess the magnitude of improvement or harms associated 
with an active intervention, a placebo- controlled randomised 
controlled trial (RCT) may be necessary.21
The variability of PROMs can be mitigated by collecting 
measurements at multiple time points to assess the trajecto-
ries of symptoms’ progression and recovery. This approach has 
several benefits: it reduces the bias caused by the patient having 
a ‘bad day’, provides information about disease trajectories and 
treatment effects over time and helps to identify participants 
with similar patterns.22
Conclusions
PROMs provide evidence on the effect of interventions on patient 
symptoms and quality of life, but by the nature of being subjec-
tive, they are prone to bias. Blinded RCTs, preferably with a 
placebo control, are crucial if the evidence of efficacy is to be 
based on PROMs. Furthermore, collecting multiple PROMS over 
time as “progression trajectories” may help to overcome the single 
measure variability. Finally, PROMs should be used in conjunction 
with objective outcomes, especially when assessment by blinded 
clinicians or researchers is not possible.
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